The Competition Bureau announced Wednesday, February 20, that it closed an investigation into allegations of abuse of dominance by Janssen, a Canadian pharmaceutical company owned by Johnson & Johnson.
The Bureau’s investigation considered whether Janssen was engaging in conduct that shielded its biologic drug, Remicade, from competition from biosimilar drugs, like Inflectra and Renflexis. This included allegations of predatory pricing, as well as other conduct that could exclude or disadvantage biosimilar competitors.
After a careful review of the facts, the Bureau concluded that there was insufficient evidence to demonstrate that Janssen’s conduct substantially lessened or prevented competition in a relevant market. Therefore, the Bureau was unable to conclude that the Competition Act has been contravened.
Matthew Boswell, Interim Commissioner of Competition, stated, “Biosimilars are vital to competition in the pharmaceutical industry. They offer Canadians the benefit of lower priced drugs where treatments can cost upwards of thousands of dollars each year. The Bureau takes all allegations of harm to competition seriously, and we are vigilantly monitoring the conduct of companies in the pharmaceutical industry.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Extends Support for Farms and Fisheries Amid Market Disruptions
May 5, 2024 by
CPI
Sony and Apollo Bid $26 Billion for Paramount Acquisition
May 5, 2024 by
CPI
Goldman Sachs Resolves Decade-Old Metal-Rigging Class Action Lawsuit
May 5, 2024 by
CPI
Italian Antitrust Ruling Puts Halt on Intesa Sanpaolo’s Fintech Ambitions
May 5, 2024 by
CPI
Google Antitrust Case: Closing Arguments Conclude
May 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI